ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

FDA News: FDA Lifts Clinical Hold On CTI’s Tosedostat

January 31, 2014

House panel investigating NIH handling of tissue specimens.

June 24, 2005

NCCS Networker Volume 5 Issue 4, Fall 1991

September 13, 1991

DOD Seeks to Fund Innovative Research In 438 Million Prostate Cancer Program

August 22, 1997

In Brief: Oliverio Moves to DEA; Kushner Blass NIH Slow Pay; DeVita Welcomes Hawkin’s Probe

February 6, 1981

Will Latest Report By Rosenberg Stir Up Critics? Some DCT Board Members Defend the Press

April 10, 1987